KR101979045B1 - 당쇄 부가 폴리펩티드 및 상기 폴리펩티드를 포함하는 의약 조성물 - Google Patents

당쇄 부가 폴리펩티드 및 상기 폴리펩티드를 포함하는 의약 조성물 Download PDF

Info

Publication number
KR101979045B1
KR101979045B1 KR1020147010631A KR20147010631A KR101979045B1 KR 101979045 B1 KR101979045 B1 KR 101979045B1 KR 1020147010631 A KR1020147010631 A KR 1020147010631A KR 20147010631 A KR20147010631 A KR 20147010631A KR 101979045 B1 KR101979045 B1 KR 101979045B1
Authority
KR
South Korea
Prior art keywords
sugar chain
leu
polypeptide
group
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020147010631A
Other languages
English (en)
Korean (ko)
Other versions
KR20140095051A (ko
Inventor
이즈미 사카모토
카즈히로 후카에
카츠나리 테즈카
케이스케 타즈루
마사토시 마에다
야스히로 카지하라
타카시 츠지
Original Assignee
가부시키가이샤 도우사 고가쿠 겐큐쇼
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 가부시키가이샤 도우사 고가쿠 겐큐쇼 filed Critical 가부시키가이샤 도우사 고가쿠 겐큐쇼
Publication of KR20140095051A publication Critical patent/KR20140095051A/ko
Application granted granted Critical
Publication of KR101979045B1 publication Critical patent/KR101979045B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
    • C07K1/026—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution by fragment condensation in solution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
KR1020147010631A 2011-10-01 2012-09-28 당쇄 부가 폴리펩티드 및 상기 폴리펩티드를 포함하는 의약 조성물 Expired - Fee Related KR101979045B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2011218793 2011-10-01
JPJP-P-2011-218793 2011-10-01
PCT/JP2012/075262 WO2013047846A1 (ja) 2011-10-01 2012-09-28 糖鎖付加ポリペプチドおよび当該ポリペプチドを含む医薬組成物

Publications (2)

Publication Number Publication Date
KR20140095051A KR20140095051A (ko) 2014-07-31
KR101979045B1 true KR101979045B1 (ko) 2019-05-15

Family

ID=47995870

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147010631A Expired - Fee Related KR101979045B1 (ko) 2011-10-01 2012-09-28 당쇄 부가 폴리펩티드 및 상기 폴리펩티드를 포함하는 의약 조성물

Country Status (16)

Country Link
US (1) US10358470B2 (cg-RX-API-DMAC7.html)
EP (1) EP2762489B1 (cg-RX-API-DMAC7.html)
JP (1) JP6153470B2 (cg-RX-API-DMAC7.html)
KR (1) KR101979045B1 (cg-RX-API-DMAC7.html)
CN (2) CN104080803B (cg-RX-API-DMAC7.html)
AU (1) AU2012317325B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014007766B1 (cg-RX-API-DMAC7.html)
CA (1) CA2850469C (cg-RX-API-DMAC7.html)
DK (1) DK2762489T3 (cg-RX-API-DMAC7.html)
IN (1) IN2014CN02982A (cg-RX-API-DMAC7.html)
MY (1) MY168902A (cg-RX-API-DMAC7.html)
PH (1) PH12014500694B1 (cg-RX-API-DMAC7.html)
RU (1) RU2636456C2 (cg-RX-API-DMAC7.html)
SG (2) SG10201602076QA (cg-RX-API-DMAC7.html)
TW (1) TWI633115B (cg-RX-API-DMAC7.html)
WO (1) WO2013047846A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2014CN02982A (cg-RX-API-DMAC7.html) 2011-10-01 2015-07-03 Glytech Inc
AU2014245917B2 (en) * 2013-03-29 2017-09-28 Glytech, Inc. Polypeptide having sialylated sugar chains attached thereto
CN114685645B (zh) * 2020-12-30 2025-03-21 深圳翰宇药业股份有限公司 一种索玛鲁肽的合成方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010015722A1 (en) * 2008-08-08 2010-02-11 Vib Vzw Cells producing glycoproteins having altered glycosylation patterns and methods and use thereof

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0237019A3 (en) * 1986-03-14 1988-03-09 Toray Industries, Inc. Interferon conjugate and production thereof using recombinant gene
AU736993B2 (en) 1997-01-16 2001-08-09 Novo Nordisk A/S Practical in vitro sialylation of recombinant glycoproteins
DE19717864C2 (de) 1997-04-23 2001-05-17 Fraunhofer Ges Forschung Humanes rekombinantes Interferon-beta, Verfahren zu seiner Herstellung und seine Verwendung
DE69936409T2 (de) * 1998-04-28 2008-04-17 Laboratoires Serono S.A., Coinsins Verfahren zur schrittweise Bindung von Polyethylenglykol (PEG) an Polypeptide
DK1656952T3 (da) 1998-10-16 2014-01-20 Biogen Idec Inc Polyalkylenglycolkonjugater af interferon beta-1A og anvendelser deraf
AU766190B2 (en) * 1998-10-16 2003-10-09 Biogen Idec Ma Inc. Interferon-beta fusion proteins and uses
US6514729B1 (en) 1999-05-12 2003-02-04 Xencor, Inc. Recombinant interferon-beta muteins
WO2001042474A2 (en) * 1999-12-08 2001-06-14 Amgen, Inc. Interferon-like molecules and uses thereof
US7795002B2 (en) * 2000-06-28 2010-09-14 Glycofi, Inc. Production of galactosylated glycoproteins in lower eukaryotes
US20030191291A1 (en) 2000-09-08 2003-10-09 Kochendoerfer Gerd G. Synthetic erythropoiesis stimulating proteins
EP1366075B1 (en) 2001-02-27 2009-05-27 Maxygen Aps New interferon beta-like molecules
PL362870A1 (en) 2001-03-15 2004-11-02 Merck Patent Gmbh Modified interferon beta with reduced immunogenicity
EP2292273A3 (en) * 2001-10-10 2011-11-23 BioGeneriX AG Remodeling and glycoconjugation of peptides
US7226903B2 (en) * 2001-10-10 2007-06-05 Neose Technologies, Inc. Interferon beta: remodeling and glycoconjugation of interferon beta
CA2469487A1 (en) 2001-12-11 2003-07-03 Aventis Pasteur Mutated hiv tat
WO2003075944A2 (en) * 2002-03-12 2003-09-18 Maxygen Aps Interferon beta-like molecules for treatment of stroke
US7943763B2 (en) 2002-07-05 2011-05-17 Otsuka Chemical Holdings Co., Ltd. Process for preparing glycopeptides having asparagine-linked oligosaccharides, and the glycopeptides
WO2004020468A2 (en) 2002-08-28 2004-03-11 Maxygen Aps Interferon beta-like molecules for treatment of cancer
DK1575531T3 (da) * 2002-09-27 2011-11-21 Biogen Idec Inc Terapier for kronisk inflammatorisk demyeliniserende polyneuropati under anvendelse af interferon-beta
AU2003277088A1 (en) 2002-10-01 2004-04-23 Xencor, Inc Interferon variants with improved properties
KR100876518B1 (ko) 2002-12-26 2008-12-31 오츠카 가가쿠 가부시키가이샤 당사슬 아스파라긴 유도체 및 그의 제조방법
WO2005019260A1 (ja) 2003-08-25 2005-03-03 Toray Industries, Inc. インターフェロンβ複合体
US20090214472A1 (en) 2004-03-01 2009-08-27 Enzon Pharmaceuticals Inc. Interferon-beta polymer conjugates
MX2007001589A (es) 2004-08-09 2007-08-02 Alios Biopharma Inc Variantes de polipeptido resistentes a proteasa, hiperglicosiladas sinteticas, formulaciones orales y metodos para utilizar las mismas.
RU2392963C2 (ru) * 2004-08-09 2010-06-27 Элиоз Байофарма, Инк. Синтетические варианты гипергликозилированного протеазо-резистентного полипептида, пероральные композиции и способы применения таких вариантов
KR100781666B1 (ko) * 2004-11-02 2007-12-03 신영기 인간 인터페론-베타 변이체
US20080219952A1 (en) * 2005-08-26 2008-09-11 Ares Trading S.A. Process For the Preparation of Glycosylated Interferon Beta
US20080038224A1 (en) * 2006-03-28 2008-02-14 Thierry Guyon Modified interferon-beta (IFN-beta) polypeptides
US20080096819A1 (en) 2006-05-02 2008-04-24 Allozyne, Inc. Amino acid substituted molecules
BRPI0813139A8 (pt) 2007-06-19 2019-01-29 Glytech Inc peptídeo glp-1 com adição de cadeia oligossacarídea
KR101534881B1 (ko) 2007-07-31 2015-07-07 가부시키가이샤 도우사 고가쿠 겐큐쇼 펩티드의 제조방법
JP2009242372A (ja) 2008-03-11 2009-10-22 Yokohama City Univ 均一な糖鎖構造を有するエリスロポエチン誘導体
BRPI0914889A2 (pt) * 2008-06-17 2015-11-24 Otsuka Chemical Co Ltd peptídeo glp-1 adicionado de cadeia oligossacarídica
AU2009283678B2 (en) * 2008-08-19 2014-01-16 Glytech, Inc. Glycoprotein production method and screening method
WO2012051615A1 (en) 2010-10-15 2012-04-19 Transgenrx, Inc. Novel vectors for production of glycosylated interferon
JP5925760B2 (ja) 2011-03-10 2016-05-25 株式会社糖鎖工学研究所 シアリル糖鎖を有する糖ペプチドの製造方法、当該製造方法に使用するシアリル糖鎖付加アミノ酸誘導体、及び当該糖ペプチド
ES2774284T3 (es) 2011-06-29 2020-07-20 Kyowa Kirin Co Ltd Método para purificar antitrombina
IN2014CN02982A (cg-RX-API-DMAC7.html) 2011-10-01 2015-07-03 Glytech Inc

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010015722A1 (en) * 2008-08-08 2010-02-11 Vib Vzw Cells producing glycoproteins having altered glycosylation patterns and methods and use thereof

Also Published As

Publication number Publication date
PH12014500694B1 (en) 2020-01-31
IN2014CN02982A (cg-RX-API-DMAC7.html) 2015-07-03
TW201321404A (zh) 2013-06-01
TWI633115B (zh) 2018-08-21
EP2762489B1 (en) 2018-03-28
SG10201602076QA (en) 2016-04-28
CA2850469C (en) 2020-07-07
US10358470B2 (en) 2019-07-23
BR112014007766A2 (pt) 2017-04-04
KR20140095051A (ko) 2014-07-31
SG11201401071YA (en) 2014-08-28
RU2636456C2 (ru) 2017-11-23
CN104080803A (zh) 2014-10-01
WO2013047846A1 (ja) 2013-04-04
EP2762489A4 (en) 2015-05-06
JP6153470B2 (ja) 2017-06-28
AU2012317325A1 (en) 2014-04-17
MY168902A (en) 2018-12-04
JPWO2013047846A1 (ja) 2015-03-30
EP2762489A9 (en) 2015-02-11
AU2012317325B2 (en) 2016-10-06
CN104080803B (zh) 2020-08-04
EP2762489A1 (en) 2014-08-06
BR112014007766B1 (pt) 2022-05-10
RU2014116550A (ru) 2015-10-27
DK2762489T3 (en) 2018-07-02
PH12014500694A1 (en) 2014-05-12
CA2850469A1 (en) 2013-04-04
US20140369964A1 (en) 2014-12-18
CN109134642A (zh) 2019-01-04

Similar Documents

Publication Publication Date Title
JP5517620B2 (ja) ペプチドの製造方法
EP2495255A1 (en) Glycosylated form of antigenic glp-1 analogue
CN102083854A (zh) 附加了糖链的glp-1肽
RU2586524C2 (ru) Способ получения гликопептида, имеющего сиалированную сахарную цепь, и способ получения производного сиалилгликоаспарагина
US20120114595A1 (en) Sugar chain-added ailim extracellular domain and method for producing same
EP2982686B1 (en) Polypeptide having sialylated sugar chains attached thereto
JP6153470B2 (ja) 糖鎖付加ポリペプチドおよび当該ポリペプチドを含む医薬組成物

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20240510

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20240510